Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Практическая пульмонология (ранее – "Атмосфера. Пульмонология и аллергология"): ISSN 2409-756X (Online), ISSN 2409-6636 (Print)
2018 / N 1

β-адреноблокаторы у больных хронической обструктивной болезнью легких и бронхиальной астмой
Т.Н. Молостова

Список литературы
1. 2017 GINA Report, Global Strategy for Asthma Management and Prevention. Available from: http://www.ginasthma.org Accessed 2018 Jun 26.
2. 2018 Global Strategy for Prevention, Diagnosis and Management of COPD. Available from: http://goldcopd.org Accessed 2018 Jun 26.
3. Chapman KR, Mannino DM, Soriano JB, Vermeire PA, Buist AS, Thun MJ, Connell C, Jemal A, Lee TA, Miravitlles M, Aldington S, Beasley R. Epidemiology and costs of chronic obstructive pulmonary disease. The European Respiratory Journal 2006 Jan;27(1):188-207.
4. Бродская О.Н. Коморбидные заболевания при бронхиальной астме. Практическая пульмонология 2017;2:3-12.
5. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. The European Respiratory Journal 2009 May;33(5):1165-85.
6. Bhatt SP, Dransfield MT. Chronic obstructive pulmonary disease and cardiovascular disease. Translational Research 2013 Oct;162(4):237-51.
7. Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 2005 Oct;128(4):2099-107.
8. Fabbri LM, Luppi F, Beghé B, Rabe KF. Complex chronic comorbidities of COPD. The European Respiratory Journal 2008 Jan;31(1):204-12.
9. Onishi K. Total management of chronic obstructive pulmonary disease (COPD) as an independent risk factor for cardiovascular disease. Journal of Cardiology 2017 Aug;70(2):128-34.
10. Овчаренко С.И., Лещенко И.В. Хроническая обструктивная болезнь легких. Руководство для практикующих врачей. Под ред. Чучалина А.Г. М.: Гэотар-Медиа; 2016.
11. Yeh JJ, Wei YF, Lin CL, Hsu WH. Association of asthma–chronic obstructive pulmonary disease overlap syndrome with coronary artery disease, cardiac dysrhythmia and heart failure: a population-based retrospective cohort study. BMJ Open 2017 Oct;7(10):e017657.
12. Namath A, Chen C, Agrawal R, Patterson AJ. b1 and b2 adrenergic receptor polymorphisms: their impact on cardiovascular physiology, disease states, and response to therapeutic agents. Journal of Critical Care 2007 Mar;26(1):2-9.
13. Brodde OE, Büscher R, Tellkamp R, Radke J, Dhein S, Insel PA. Blunted cardiac responses to receptor activation in subjects with Thrl64Ile b2-adrenoceptors.Circulation 2001 Feb;103(8):1048-50.
14. Молостова Т.Н. Лекарственные повреждения легких при медикаментозной терапии. В кн.: Респираторная медицина. Руководство для практикующих врачей. Под ред. Чучалина А.Г. М.: Гэотар-Медиа; 2017.
15. McGraw DW, Forbes SL, Mak JC, Witte DP, Carrigan PE, Leikauf GD, Liggett SB. Transgenic overexpression of beta2-adrenergic receptors in airway epithelial cells decreases bronchoconstriction. American Journal of Physiology – Lung Cellular and Molecular Physiology 2000 Aug;279(2):L379-89.
16. Nguyen LP, Omoluabi O, Parra S, Frieske JM, Clement C, Ammar-Aouchiche Z, Ho SB, Ehre C, Kesimer M, Knoll BJ, Tuvim MJ, Dickey BF, Bond RA. Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model. American Journal of Respiratory Cell and Molecular Biology 2008 Mar;38(3):256-62.
17. Молостова Т.Н. Генетические различия b2-адренорецепторов и их клиническое значение. Практическая пульмонология 2017;2:63-9.
18. Wagoner LE, Craft LL, Singh B, Suresh DP, Zengel PW, McGuire N, Abraham WT, Chenier TC, Dorn GW 2nd, Liggett SB. Polymorphisms of the b2-adrenergic receptor determine exercise capacity in patients with heart failure. Circulation Research 2000 Apr;86(8):834-40.
19. Liggett SB, Wagoner LE, Craft LL, Hornung RW, Hoit BD, McIntosh TC, Walsh RA. The Ile164 b2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. The Journal of Clinical Investigation 1998 Oct;102(8):1534-9.
20. Timmermann B, Mo R, Luft FC, Gerdts E, Busjahn A, Omvik P, Li GH, Schuster H, Wienker TF, Hoehe MR, Lund-Johansen P. Beta-2-adrenoreceptor genetic variation is associated with genetic predisposition to essential hypertension: the Bergen Blood Pressure Study. Kidney International 1998 Jun;53(6):1455-60.
21. Iaccarino G, Lanni F, Cipolletta E, Trimarco V, Izzo R, Iovino GL, De Luca N, Trimarco B. The Glu27 allele of the [beta] 2 adrenergic receptor increases the risk of cardiac hypertrophy in hypertension. Journal of Hypertension 2004 Nov;22(11):2117-22.
22. Клиническая фармакология. Под ред. Кукеса В.Г. 4-е изд., перераб. и доп. М.: Гэотар-Медиа; 2009.
23. Руководство по кардиологии. В 3-х т. Под ред. Сторожакова Г.И., Горбаченкова А.А. Т. 3. М.: Гэотар-Медиа; 2009: 512.
24. Федеральное руководство по использованию лекарственных средств (формулярная система). Вып. ХVIII. Под ред. Чучалина А.Г., Хохлова А.Л. М.: Видокс; 2017: 116-21.
25. Ухолкина Г.Б. Бета-блокаторы: современное состояние вопроса. Русский медицинский журнал 2010;22:1360-5.
26. Шилов А.М., Осия А.О., Тарасенко О.Ф., Свиридова А.Ю. Место кардиоселективных b-адреноблокаторов в практике лечения сердечно-сосудистых заболеваний. Доступно по: https://www.rmj.ru/articles/kardiologiya/Mesto_kardioselektivnyh_946adrenoblokatorov__v_praktike_lecheniya_serdechnososudistyh__zabolevaniy/#ixzz56irWS6p6. Ссылка активна на 26.06.2018.
27. Gauld DR, Pain MC, Rubinfeld AR. Beta-blocking drugs and airways obstruction. The Medical Journal of Australia 1979 Jul:2(2):88.
28. Raine JM, Palazzo MG, Kerr JH, Sleight P. Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane. British Medical Journal (Clinical Research ed.) 1981 Feb:282(6263):548-9.
29. Williams IP, Millard FJ. Severe asthma after inadvertent ingestion of oxprenolol. Thorax 1980 Feb;35(2):160.
30. Chester EH, Schwartz HJ, Fleming GM. Adverse effect of propranolol on airway function in nonasthmatic chronic obstructive lung disease. Chest 1981 May;79(5):540-4.
31. Chang CL, Mills GD, McLachlan JD, Karalus NC, Hancox RJ. Cardio-selective and non-selective beta-blockers in chronic obstructive pulmonary disease: effects on bronchodilator response and exercise. Internal Medicine Journal 2010 Mar;40(3):193-200.
32. van der Woude HJ, Zaagsma J, Postma DS, Winter TH, van Hulst M, Aalbers R. Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers. Chest 2005 Mar;127(3):818-24.
33. Olenchock BA, Fonarow GG, Pan W, Hernandez A, Cannon CP; Get With The Guidelines Steering Committee. Current use of beta blockers in patients with reactive airway disease who are hospitalized with acute coronary syndromes. American Journal of Cardiology 2009 Feb;103(3):295-300.
34. Mascarenhas J, Azevedo A, Bettencourt P. Coexisting chronic obstructive pulmonary disease and heart failure: implications for treatment, course and mortality. Current Opinion in Pulmonary Medicine 2010 Mar;16(2):106-11.
35. Lipworth B, Wedzicha J, Devereux G, Vestbo J, Dransfield MT. Beta-blockers in COPD: time for reappraisal. The European Respiratory Journal 2016 Sep;48(3):880-8.
36. NICE (National Institute for Health and Care Excellence). Multimorbidity: clinical assessment and management, in press. 2016. Available from: https://www.nice.org.uk/guidance/ng56 Accessed 2018 Jun 25.
37. Andrus MR, Holloway KP, Clark DB. Use of beta-blockers in patients with COPD. Annals of Pharmacotherapy 2004 Jan;38(1):142-5.
38. Buch P, Friberg J, Scharling H, Lange P, Prescott E. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. The European Respiratory Journal 2003 Jun;21(6):1012-6.
39. Singh S, Loke YK, Enright P, Furberg CD. Pro-arrhythmic and pro-ischaemic of inhaled anticholinergic medications. Thorax 2013 Jan;68(1):114-6.
40. Wilchesky M, Ernst P, Brophy JM, Platt RW, Suissa S. Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort. Chest 2012 Aug:142(2):303-11.
41. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004 Jun:125(6):2309-21.
42. Tashkin DP, Fabbri LM. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respiratory Research 2010 Oct;11:149.
43. Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, Dusser D, Joseph E, Kattenbeck S, Koenen-Bergmann M, Pledger G, Calverley P; TIOSPIR Investigators. Tiotropium Respimat inhaler and the risk of death in COPD. The New England Journal of Medicine 2013 Oct;369(16):1491-501.
44. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. The New England Journal of Medicine 2008 Oct;359(15):1543-54.
45. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. The European Respiratory Journal 2003 Jan;21(1):74-81.
46. Wilchesky M, Ernst P, Brophy JM, Platt RW, Suissa S. Bronchodilatator use and the risk of arrhythmia in COPD: part 1: Saskatchewan cohort study. Chest 2012 Aug;142(2):298-304.
47. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the mamagement of patiens with atriallation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhytm Society. Circulation 2014;130(23):2071-104.
48. Ohta K, Fukuchi Y, Grouse L, Mizutani R, Rabe KF, Rennard SI, Zhong NS. A prospective clinical study of theophylline safety in 3810 elderly with asthma or COPD. Respiratory Medicine 2004 Oct;98(10):1016-24.
49. Everly MJ, Heaton PC, Cluxton RJ Jr. Beta-blocker underuse in secondary prevention of myocardial infarction. Annals of Pharmacotherapy 2004 Feb;38(2):286-93.
50. Lim KP, Loughrey S, Musk M, Lavender M, Wrobel JP. Beta-blocker under-use in COPD patients. International Journal of Chronic Obstructive Pulmonary Disease 2017 Oct 17;12:3041-6.
51. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A; ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal 2012 Jul;33(14):1787-847.
52. Bhatt SP, Wells JM, Kinney GL, Washko GR Jr, Budoff M, Kim YI, Bailey WC, Nath H, Hokanson JE, Silverman EK, Crapo J, Dransfield MT; COPDGene Investigators. b-Blockers are associated with a reduction in COPD exacerbations. Thorax 2016 Jan;71(1):8-14.
53. Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Archives of Internal Medicine 2010 May;170(10):880-7.
54. Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. British Medical Journal 2011 May;342:d2549.
55. Etminan M, Jafari S, Carleton B, FitzGerald JM. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulmonary Medicine 2012 Sep;12:48.
56. Leitao Filho FS, Alotaibi NM, Yamasaki K, Ngan DA, Sin DD. The role of beta-blockers in the management of chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine 2018 Feb;12(2):125-35.
57. Pité H, da Cruz MB, Morais-Almeida M. Obstructive lung diseases and beta-blockers: Where do we stand? European Journal of Internal Medicine 2016 Oct;34:e32-3.
58. Petta V, Perlikos F, Loukides S, Bakakos P, Chalkias A, Iacovidou N, Xanthos T, Tsekoura D, Hillas G. Therapeutic effects of the combination of inhaled beta2-agonists and beta-blockers in COPD patients with cardiovascular disease. Heart Failure Reviews 2017 Nov;22(6):753-63.
59. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. The New England Journal of Medicine 1998 Aug;339(8):489-97.
60. Stefan MS, Rothberg MB, Priya A, Pekow PS, Au DH, Lindenauer PK. Association between b-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. Thorax 2012 Nov;67(11):977-84.
61. Nodari S, Metra M, Dei Cas L. Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. European Journal of Heart Failure 2003 Oct;5(5):621-7.
62. Kubota Y, Asai K, Furuse E, Nakamura S, Murai K, Tsukada YT, Shimizu W. Impact of b-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 2015 Mar;10:515-23.
63. Baker JG, Wilcox RG. b-Blockers, heart disease and COPD: current controversies and uncertainties. Thorax 2017 Mar;72(3):271-6.
64. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blocker use in patients with reversible airway disease. The Cochrane Database of Systematic Reviews 2001;(2):CD002992.
65. Morales DR, Jackson C, Lipworth BJ, Donnan PT, Guthrie B. Adverse respiratory effect of acute b-blocker exposure in asthma: a systematic review and meta-analysis of randomized controlled trials. Chest 2014 Apr;145(4):779-86.
66. Short PM, Williamson PA, Anderson WJ, Lipworth BJ. Randomised placebo-controlled trial to evaluate chronic dosing effects of propranolol in asthma. American Journal of Respiratory and Critical Care Medicine 2013 Jun;187(12):1308-14.
67. Jabbal S, Anderson W, Short P, Morrison A, Manoharan A, Lipworth BJ. Cardiopulmonary interactions with beta-blockers and inhaled therapy in COPD. QJM 2017 Jul 24. doi: 10.1093/qjmed/hcx155. [Epub ahead of print].
68. Овчаренко С.И., Литвинова И.В., Маколкин В.И. Селективные b-адреноблокаторы (небиволол и метопролола сукцинат) в терапии больных артериальной гипертонией и/или ишемической болезнью сердца в сочетании с бронхообструктивным синдромом: оценка эффективности и безопасности. Пульмонология 2008;3:28-34.
69. Jabbal S, Lipworth BJ. Tolerability of bisoprolol on domiciliary spirometry in COPD. Lung 2018 Feb;196(1):11-4.
70. Key A, Parry M, West MA, Asher R, Jack S, Duffy N, Torella F, Walker PP. Effect of b-blockade on lung function, exercise performance and dynamic hyperinflation in people with arterial vascular disease with and without COPD. BMJ Open Respiratory Research 2017 Apr;4(1):e000164.
71. Neef PA, Burrell LM, McDonald CF, Irving LB, Johnson DF, Steinfort DP. Commencement of cardioselective beta-blockers during hospitalisation for acute exacerbations of chronic obstructive pulmonary disease. Internal Medicine Journal 2017 Sep;47(9):1043-50.
72. Duffy S, Marron R, Voelker H, Albert R, Connett J, Bailey W, Casaburi R, Cooper JA Jr, Curtis JL, Dransfield M, Han MK, Make B, Marchetti N, Martinez F, Lazarus S, Niewoehner D, Scanlon PD, Sciurba F, Scharf S, Reed RM, Washko G, Woodruff P, McEvoy C, Aaron S, Sin D, Criner GJ; NIH COPD Clinical Research Network and the Canadian Institutes of Health Research. Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD). Respiratory Research 2017 Jun;18(1):124.
73. Morales DR, Lipworth BJ, Donnan PT, Jackson C, Guthrie B. Respiratory effect of beta-blockers in people with asthma and cardiovascular disease: population-based nested case control study. BMC Medicine 2017 Jan;15(1):18.
74. Huang YL, Lai CC, Wang YH, Wang CY, Wang JY, Wang HC, Yu CJ, Chen L. Impact of selective and nonselective beta-blockers on the risk of severe exacerbations in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease 2017 Oct 11;12:2987-96.
75. Farland MZ, Peters CJ, Williams JD, Bielak KM, Heidel RE, Ray SM. β-Blocker use and incidence of chronic obstructive pulmonary disease exacerbations. Annals of Pharmacotherapy 2013 May;47(5):651-6.
76. Brooks TW, Creekmore FM, Young DC, Asche CV, Oberg B, Samuelson WM. Rates of hospitalizations and emergency department visits in patients with asthma and chronic obstructive pulmonary disease taking beta-blockers. Pharmacotherapy 2007 May;27(5):684-90.
77. Morales DR, Dreischulte T, Lipworth BJ, Donnan PT, Jackson C, Guthrie B. Respiratory effect of beta-blocker eye drops in asthma: population-based study and meta-analysis of clinical trials. British Journal of Clinical Pharmacology 2016 Sep;82(3):814-22.
78. Everitt DE, Avorn J. Systemic effects of medications used to treat glaucoma. Annals of Internal Medicine 1990 Jan;112(2):120-5.

References
1. 2017 GINA Report, Global Strategy for Asthma Management and Prevention. Available from: http://www.ginasthma.org Accessed 2018 Jun 26.
2. 2018 Global Strategy for Prevention, Diagnosis and Management of COPD. Available from: http://goldcopd.org Accessed 2018 Jun 26.
3. Chapman KR, Mannino DM, Soriano JB, Vermeire PA, Buist AS, Thun MJ, Connell C, Jemal A, Lee TA, Miravitlles M, Aldington S, Beasley R. Epidemiology and costs of chronic obstructive pulmonary disease. The European Respiratory Journal 2006 Jan;27(1):188-207.
4. Brodskaya ON. Comorbidities in patients with asthma. Practical Pulmonology 2017;2:3-12 (In Russian).
5. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. The European Respiratory Journal 2009 May;33(5):1165-85.
6. Bhatt SP, Dransfield MT. Chronic obstructive pulmonary disease and cardiovascular disease. Translational Research 2013 Oct;162(4):237-51.
7. Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 2005 Oct;128(4):2099-107.
8. Fabbri LM, Luppi F, Beghé B, Rabe KF. Complex chronic comorbidities of COPD. The European Respiratory Journal 2008 Jan;31(1):204-12.
9. Onishi K. Total management of chronic obstructive pulmonary disease (COPD) as an independent risk factor for cardiovascular disease. Journal of Cardiology 2017 Aug;70(2):128-34.
10. Ovcharenko SI, Leshchenko IV. Chronic obstructive pulmonary disease: a guide. Chuchalin AG, editor. Moscow: Geotar-Media; 2016. (In Russian).
11. Yeh JJ, Wei YF, Lin CL, Hsu WH. Association of asthma–chronic obstructive pulmonary disease overlap syndrome with coronary artery disease, cardiac dysrhythmia and heart failure: a population-based retrospective cohort study. BMJ Open 2017 Oct;7(10):e017657.
12. Namath A, Chen C, Agrawal R, Patterson AJ. β1 and β2 Adrenergic receptor polymorphisms: their impact on cardiovascular physiology, disease states, and response to therapeutic agents. Journal of Critical Care 2007 Mar;26(1):2-9.
13. Brodde OE, Büscher R, Tellkamp R, Radke J, Dhein S, Insel PA. Blunted cardiac responses to receptor activation in subjects with Thrl64Ile β2-adrenoceptors.Circulation 2001 Feb;103(8):1048-50.
14. Molostova TN. Drug-induced lung injuries in drug therapy. In: Respiratory medicine: a guide. Chuchalin AG, editor. Moscow: Geotar-Media; 2017. (In Russian).
15. McGraw DW, Forbes SL, Mak JC, Witte DP, Carrigan PE, Leikauf GD, Liggett SB. Transgenic overexpression of beta2-adrenergic receptors in airway epithelial cells decreases bronchoconstriction. American Journal of Physiology – Lung Cellular and Molecular Physiology 2000 Aug;279(2):L379-89.
16. Nguyen LP, Omoluabi O, Parra S, Frieske JM, Clement C, Ammar-Aouchiche Z, Ho SB, Ehre C, Kesimer M, Knoll BJ, Tuvim MJ, Dickey BF, Bond RA. Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model. American Journal of Respiratory Cell and Molecular Biology 2008 Mar;38(3):256-62.
17. Molostova TN. Genetic variability of β2-adrenoreceptors and its clinical importance. Practical Pulmonology 2017;2:63-9 (In Russian).
18. Wagoner LE, Craft LL, Singh B, Suresh DP, Zengel PW, McGuire N, Abraham WT, Chenier TC, Dorn GW 2nd, Liggett SB. Polymorphisms of the β2-adrenergic receptor determine exercise capacity in patients with heart failure. Circulation Research 2000 Apr;86(8):834-40.
19. Liggett SB, Wagoner LE, Craft LL, Hornung RW, Hoit BD, McIntosh TC, Walsh RA. The Ile164 β2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. The Journal of Clinical Investigation 1998 Oct;102(8):1534-9.
20. Timmermann B, Mo R, Luft FC, Gerdts E, Busjahn A, Omvik P, Li GH, Schuster H, Wienker TF, Hoehe MR, Lund-Johansen P. Beta-2-adrenoreceptor genetic variation is associated with genetic predisposition to essential hypertension: the Bergen Blood Pressure Study. Kidney International 1998 Jun;53(6):1455-60.
21. Iaccarino G, Lanni F, Cipolletta E, Trimarco V, Izzo R, Iovino GL, De Luca N, Trimarco B. The Glu27 allele of the [beta] 2 adrenergic receptor increases the risk of cardiac hypertrophy in hypertension. Journal of Hypertension 2004 Nov;22(11):2117-22.
22. Clinical pharmacology. Kukes VG, editor. 4th ed. Moscow: Geotar-Media; 2009. Chapter 7. (In Russian).
23. Cardiology guidelines. 3 vol. set. Storozhakov GI, Gorbachenkov AA, editors. Moscow: Geotar-Media; 2009:III:512. (In Russian).
24. Federal guidance on the use of drugs (formulary system). Сhuchalin AG, Khokhlov AL, editors. Moscow: Vidox; 2017:116-21 (In Russian).
25. Ukholkina GB. Beta-blockers: current status of the issue. Russian Medical Journal 2010;22:1360-5 (In Russian).
26. Shilov AM, Osiya AO, Tarasenko OF, Sviridova AYu. Cardioselective β-blockers in the treatment of cardiovascular diseases. Available from: https://www.rmj.ru/articles/kardiologiya/Mesto_kardioselektivnyh_946adrenoblokatorov__v_praktike_lecheniya_serdechnososudistyh__zabolevaniy/#ixzz56irWS6p6. Accessed 2018 Jun 27 (In Russian).
27. Gauld DR, Pain MC, Rubinfeld AR. Beta-blocking drugs and airways obstruction. The Medical Journal of Australia 1979 Jul:2(2):88.
28. Raine JM, Palazzo MG, Kerr JH, Sleight P. Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane. British Medical Journal (Clinical Research ed.) 1981 Feb:282(6263):548-9.
29. Williams IP, Millard FJ. Severe asthma after inadvertent ingestion of oxprenolol. Thorax 1980 Feb;35(2):160.
30. Chester EH, Schwartz HJ, Fleming GM. Adverse effect of propranolol on airway function in nonasthmatic chronic obstructive lung disease. Chest 1981 May;79(5):540-4.
31. Chang CL, Mills GD, McLachlan JD, Karalus NC, Hancox RJ. Cardio-selective and non-selective beta-blockers in chronic obstructive pulmonary disease: effects on bronchodilator response and exercise. Internal Medicine Journal 2010 Mar;40(3):193-200.
32. van der Woude HJ, Zaagsma J, Postma DS, Winter TH, van Hulst M, Aalbers R. Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers. Chest 2005 Mar;127(3):818-24.
33. Olenchock BA, Fonarow GG, Pan W, Hernandez A, Cannon CP; Get With The Guidelines Steering Committee. Current use of beta blockers in patients with reactive airway disease who are hospitalized with acute coronary syndromes. American Journal of Cardiology 2009 Feb;103(3):295-300.
34. Mascarenhas J, Azevedo A, Bettencourt P. Coexisting chronic obstructive pulmonary disease and heart failure: implications for treatment, course and mortality. Current Opinion in Pulmonary Medicine 2010 Mar;16(2):106-11.
35. Lipworth B, Wedzicha J, Devereux G, Vestbo J, Dransfield MT. Beta-blockers in COPD: time for reappraisal. The European Respiratory Journal 2016 Sep;48(3):880-8.
36. NICE (National Institute for Health and Care Excellence). Multimorbidity: clinical assessment and management, in press. 2016. Available from: https://www.nice.org.uk/guidance/ng56 Accessed 2018 Jun 25.
37. Andrus MR, Holloway KP, Clark DB. Use of beta-blockers in patients with COPD. Annals of Pharmacotherapy 2004 Jan;38(1):142-5.
38. Buch P, Friberg J, Scharling H, Lange P, Prescott E. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. The European Respiratory Journal 2003 Jun;21(6):1012-6.
39. Singh S, Loke YK, Enright P, Furberg CD. Pro-arrhythmic and pro-ischaemic of inhaled anticholinergic medications. Thorax 2013 Jan;68(1):114-6.
40. Wilchesky M, Ernst P, Brophy JM, Platt RW, Suissa S. Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort. Chest 2012 Aug:142(2):303-11.
41. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004 Jun:125(6):2309-21.
42. Tashkin DP, Fabbri LM. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respiratory Research 2010 Oct;11:149.
43. Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, Dusser D, Joseph E, Kattenbeck S, Koenen-Bergmann M, Pledger G, Calverley P; TIOSPIR Investigators. Tiotropium Respimat inhaler and the risk of death in COPD. The New England Journal of Medicine 2013 Oct;369(16):1491-501.
44. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. The New England Journal of Medicine 2008 Oct;359(15):1543-54.
45. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. The European Respiratory Journal 2003 Jan;21(1):74-81.
46. Wilchesky M, Ernst P, Brophy JM, Platt RW, Suissa S. Bronchodilatator use and the risk of arrhythmia in COPD: part 1: Saskatchewan cohort study. Chest 2012 Aug;142(2):298-304.
47. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the mamagement of patiens with atriallation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhytm Society. Circulation 2014;130(23):2071-104.
48. Ohta K, Fukuchi Y, Grouse L, Mizutani R, Rabe KF, Rennard SI, Zhong NS. A prospective clinical study of theophylline safety in 3810 elderly with asthma or COPD. Respiratory Medicine 2004 Oct;98(10):1016-24.
49. Everly MJ, Heaton PC, Cluxton RJ Jr. Beta-blocker underuse in secondary prevention of myocardial infarction. Annals of Pharmacotherapy 2004 Feb;38(2):286-93.
50. Lim KP, Loughrey S, Musk M, Lavender M, Wrobel JP. Beta-blocker under-use in COPD patients. International Journal of Chronic Obstructive Pulmonary Disease 2017 Oct 17;12:3041-6.
51. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A; ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal 2012 Jul;33(14):1787-847.
52. Bhatt SP, Wells JM, Kinney GL, Washko GR Jr, Budoff M, Kim YI, Bailey WC, Nath H, Hokanson JE, Silverman EK, Crapo J, Dransfield MT; COPDGene Investigators. β-Blockers are associated with a reduction in COPD exacerbations. Thorax 2016 Jan;71(1):8-14.
53. Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Archives of Internal Medicine 2010 May;170(10):880-7.
54. Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. British Medical Journal 2011 May;342:d2549.
55. Etminan M, Jafari S, Carleton B, FitzGerald JM. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulmonary Medicine 2012 Sep;12:48.
56. Leitao Filho FS, Alotaibi NM, Yamasaki K, Ngan DA, Sin DD. The role of beta-blockers in the management of chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine 2018 Feb;12(2):125-35.
57. Pité H, da Cruz MB, Morais-Almeida M. Obstructive lung diseases and beta-blockers: Where do we stand? European Journal of Internal Medicine 2016 Oct;34:e32-3.
58. Petta V, Perlikos F, Loukides S, Bakakos P, Chalkias A, Iacovidou N, Xanthos T, Tsekoura D, Hillas G. Therapeutic effects of the combination of inhaled beta2-agonists and beta-blockers in COPD patients with cardiovascular disease. Heart Failure Reviews 2017 Nov;22(6):753-63.
59. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. The New England Journal of Medicine 1998 Aug;339(8):489-97.
60. Stefan MS, Rothberg MB, Priya A, Pekow PS, Au DH, Lindenauer PK. Association between β-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. Thorax 2012 Nov;67(11):977-84.
61. Nodari S, Metra M, Dei Cas L. Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. European Journal of Heart Failure 2003 Oct;5(5):621-7.
62. Kubota Y, Asai K, Furuse E, Nakamura S, Murai K, Tsukada YT, Shimizu W. Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 2015 Mar;10:515-23.
63. Baker JG, Wilcox RG. β-Blockers, heart disease and COPD: current controversies and uncertainties. Thorax 2017 Mar;72(3):271-6.
64. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blocker use in patients with reversible airway disease. The Cochrane Database of Systematic Reviews 2001;(2):CD002992.
65. Morales DR, Jackson C, Lipworth BJ, Donnan PT, Guthrie B. Adverse respiratory effect of acute β-blocker exposure in asthma: a systematic review and meta-analysis of randomized controlled trials. Chest 2014 Apr;145(4):779-86.
66. Short PM, Williamson PA, Anderson WJ, Lipworth BJ. Randomised placebo-controlled trial to evaluate chronic dosing effects of propranolol in asthma. American Journal of Respiratory and Critical Care Medicine 2013 Jun;187(12):1308-14.
67. Jabbal S, Anderson W, Short P, Morrison A, Manoharan A, Lipworth BJ. Cardiopulmonary interactions with beta-blockers and inhaled therapy in COPD. QJM 2017 Jul 24. doi: 10.1093/qjmed/hcx155. [Epub ahead of print].
68. Ovcharenko SI, Litvinova IV, Makolkin VI. Selective β-blockers (nebivolol and metoprolol hemisuccinate) in therapy of patients with hypertension and/or ischaemic heart disease and concomitant bronchoobstructive syndrome: evaluation of efficacy and safety. Russian Pulmonology 2008;3:28-34 (In Russian).
69. Jabbal S, Lipworth BJ. Tolerability of bisoprolol on domiciliary spirometry in COPD. Lung 2018 Feb;196(1):11-4.
70. Key A, Parry M, West MA, Asher R, Jack S, Duffy N, Torella F, Walker PP. Effect of β-blockade on lung function, exercise performance and dynamic hyperinflation in people with arterial vascular disease with and without COPD. BMJ Open Respiratory Research 2017 Apr;4(1):e000164.
71. Neef PA, Burrell LM, McDonald CF, Irving LB, Johnson DF, Steinfort DP. Commencement of cardioselective beta-blockers during hospitalisation for acute exacerbations of chronic obstructive pulmonary disease. Internal Medicine Journal 2017 Sep;47(9):1043-50.
72. Duffy S, Marron R, Voelker H, Albert R, Connett J, Bailey W, Casaburi R, Cooper JA Jr, Curtis JL, Dransfield M, Han MK, Make B, Marchetti N, Martinez F, Lazarus S, Niewoehner D, Scanlon PD, Sciurba F, Scharf S, Reed RM, Washko G, Woodruff P, McEvoy C, Aaron S, Sin D, Criner GJ; NIH COPD Clinical Research Network and the Canadian Institutes of Health Research. Effect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD). Respiratory Research 2017 Jun;18(1):124.
73. Morales DR, Lipworth BJ, Donnan PT, Jackson C, Guthrie B. Respiratory effect of beta-blockers in people with asthma and cardiovascular disease: population-based nested case control study. BMC Medicine 2017 Jan;15(1):18.
74. Huang YL, Lai CC, Wang YH, Wang CY, Wang JY, Wang HC, Yu CJ, Chen L. Impact of selective and nonselective beta-blockers on the risk of severe exacerbations in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease 2017 Oct 11;12:2987-96.
75. Farland MZ, Peters CJ, Williams JD, Bielak KM, Heidel RE, Ray SM. β-Blocker use and incidence of chronic obstructive pulmonary disease exacerbations. Annals of Pharmacotherapy 2013 May;47(5):651-6.
76. Brooks TW, Creekmore FM, Young DC, Asche CV, Oberg B, Samuelson WM. Rates of hospitalizations and emergency department visits in patients with asthma and chronic obstructive pulmonary disease taking beta-blockers. Pharmacotherapy 2007 May;27(5):684-90.
77. Morales DR, Dreischulte T, Lipworth BJ, Donnan PT, Jackson C, Guthrie B. Respiratory effect of beta-blocker eye drops in asthma: population-based study and meta-analysis of clinical trials. British Journal of Clinical Pharmacology 2016 Sep;82(3):814-22.
78. Everitt DE, Avorn J. Systemic effects of medications used to treat glaucoma. Annals of Internal Medicine 1990 Jan;112(2):120-5.
  

[ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]